<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03612960</url>
  </required_header>
  <id_info>
    <org_study_id>9276</org_study_id>
    <nct_id>NCT03612960</nct_id>
  </id_info>
  <brief_title>Measuring Neuroadaptations in Response to Very Low Nicotine Content Cigarettes</brief_title>
  <official_title>Measuring Neuroadaptations in Response to Very Low Nicotine Content Cigarettes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to determine if switching to very low nicotine content
      cigarettes changes the function of brain circuitry involved in incentive salience and
      executive control among dependent smokers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a double-blind, randomized controlled trial, dependent smokers will be randomized to a
      6-week very low nicotine content (VLNC) cigarette condition (N=50) or a 6-week normal
      nicotine content cigarette control condition (NNC; N=25). Participants will undergo
      functional magnetic resonance imaging (fMRI) scans at baseline and 6-weeks to investigate the
      nicotine-related modulation of brain circuitry involved in incentive salience valuation and
      executive control. Imaging tasks will engage the incentive salience of smoking cues and
      non-smoking rewards and executive control functions to identify changes in functional
      activity within, and effective connectivity between, known salience and executive control
      brain circuitry. A novel fMRI task using specialized odor presentation equipment and fMRI
      sequences will assess neural cue reactivity to smoke odors.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Temporarily suspended due to Pandemic
  </why_stopped>
  <start_date type="Actual">February 20, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in blood oxygen level dependent (BOLD) activity collected by fMRI</measure>
    <time_frame>Changes in BOLD from baseline to the 6-week visit.</time_frame>
    <description>Effect of nicotine content on changes in task-related functional brain activation over 6-weeks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Tobacco Dependence</condition>
  <arm_group>
    <arm_group_label>Very low nicotine content cigarettes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research cigarettes with very low nicotine content (0.03 mg/cigarette) compared to usual brand cigarettes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal nicotine content cigarettes</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Research cigarettes with normal nicotine content (0.8 mg/cigarette) similar to usual brand cigarettes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Very low nicotine content cigarettes</intervention_name>
    <description>Very low nicotine content cigarettes</description>
    <arm_group_label>Very low nicotine content cigarettes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal nicotine content cigarettes</intervention_name>
    <description>Normal nicotine content cigarettes</description>
    <arm_group_label>Normal nicotine content cigarettes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  21-60 years old

          -  Smoke &gt;5 cigarettes per day

          -  &gt;1 year of daily smoking

          -  No quit attempt in prior month and not planning to quit smoking within next 3 months

          -  Able to understand and consent to study procedures

          -  High school or lower educational attainment or annual household income &lt; $50,000

          -  Plan to live in local area next 3 months

          -  Women not pregnant or nursing and taking steps to avoid pregnancy

          -  Able to read and write in English

        Exclusion Criteria:

          -  Use of non-cigarette tobacco products in the past 7 days

          -  Use of illicit substances more than once a week in the past 3 months (excluding
             marijuana)

          -  Current alcohol abuse impairing participation

          -  MRI safety contraindications (e.g., metal implants, claustrophobia)

          -  Unstable or significant medical conditions (e.g., COPD, coronary heart disease)

          -  Major neurological conditions or brain trauma

          -  Major surgeries planned in next 3 months

          -  Use of smoking cessation medication in prior month (e.g., varenicline, patch)

          -  Uncontrolled serious mental illness, suicidality, or inpatient psychiatric
             hospitalization in the past 6 months

          -  Unwillingness to provide urine samples

          -  Unwilling to smoke study assigned cigarettes for the remainder of the trial

          -  Plans to move or take extended travel out of the area in the next 3 months

          -  Any other condition or situation that would, in the investigator's opinion, make it
             unlikely that the participant could comply with the study protocol

          -  Self-reported color blindness

          -  Left-handedness

          -  Smell dysfunction as determined via standardized assessment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Hobkirk, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Health</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Andrea Hobkirk, PhD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Tobacco</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Smoking</keyword>
  <keyword>Functional magnetic resonance imaging</keyword>
  <keyword>Addiction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

